ClinicalTrials.Veeva

Menu

Intervention to Change Attributions That Are Negative (ICAN)

Indiana University logo

Indiana University

Status

Completed

Conditions

Brain Injuries
Traumatic Brain Injury
Brain Injuries, Traumatic
Brain, Trauma
Trauma, Brain

Treatments

Behavioral: ICAN

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT03648476
1R21HD094232-01 (U.S. NIH Grant/Contract)
1806829789

Details and patient eligibility

About

ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. This is a randomized waitlist control trial. The length of time in the trial is approximately 15 weeks and the intervention is 6 weeks long.

Full description

ICAN is the first treatment to target hostile attributions after TBI, making it a novel anger/ aggression management approach in this population. Since the investigator's prior research shows that stronger hostile attributions are associated with poorer perspective taking,39 ICAN employs a unique perspective-positioning technique to train perspective taking and reduce hostile attributions. After recalling a personal situation in which others' ambiguous actions led to an unpleasant outcome, participants will explore different perspectives: sitting or standing in one position, s/he will explore his or her own thoughts and feelings (self-perspective), then move to a different position to experience the other person's perspective, eliciting their thoughts and feelings.

In 40 participants with TBI, we will conduct a Phase I, randomized waitlist controlled trial with 4 data collection points: Baseline; Week 1; Week 8 (post-treatment for ICAN; post-wait period for WLC); Week 15 (WLC post-treatment).

Enrollment

28 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • History of complicated mild to severe TBI (injury due to an external physical force), with injury severity being defined either by Glasgow Coma Score at time of injury (≤12), or post-traumatic amnesia (≥1 day), or loss of consciousness (≥30 minutes), or positive head CT scan consistent with TBI.
  • At least 18 years of age or older;
  • ≥1 year post-injury;
  • Have adequate vision, hearing, and speech/ language skills to participate in assessments and group therapy (determined based on interaction with the participant at screening)
  • Have adequate reading comprehension (due to the primary assessment involving written scenarios)
  • Have abnormal scores of negative attributions or perspective taking (determined at T0 screening)
  • Have above average aggression (prescreened on telephone, and confirmed T0 screening).
  • No anticipated medication changes for emotions/ behavior during length of study participation; medications for emotions/ behavior must be stable within last 30 days prior to consent at T0 (Screening)
  • Have reliable mode of transportation

Exclusion criteria

  • Pre-morbid neurological disorders that could affect mood and cognition (e.g. stroke); does not include controlled seizures
  • Progressive central nervous system disorders (e.g. dementia, Parkinson's)
  • Developmental disability (e.g., autism, developmental delay);
  • Major psychiatric disorders (e.g. schizophrenia, Borderline Personality Disorder);
  • Severe Depression and/or perceived risk to self or others (mental health resources will be provided and if suicide risk, approved suicide protocol will be utilized);
  • Currently receiving active behavioral therapy for anger.
  • On drug research study for irritability, anger, aggression

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

28 participants in 2 patient groups

ICAN
Experimental group
Description:
6-week group therapy intervention with clinical RA comprised of 6 90-120 minute sessions beginning after Time 1 testing
Treatment:
Behavioral: ICAN
WLC: Waitlist Control
Other group
Description:
WLC participants will delay treatment until after time two testing 8-weeks from time one testing. Participants will then begin 6 90-120 minute therapy sessions.
Treatment:
Behavioral: ICAN

Trial documents
2

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems